ADCURAM sells Nuvisan’s Clinical Drug Development Business to Japanese Strategic Investor Linical

Munich-based industrial holding ADCURAM Group AG and its Nuvisan Pharma Holding GmbH subsidiary have divested their Clinical Drug Development activities to Linical Co. Ltd. a leading Japanese clinical research organization (CRO). The complex carve out transaction was settled with economic effect as of 30 November 2014.

The core of this transaction constitutes the Munich and Neu-Ulm based NUVISAN CDD Holding GmbH (NUVISAN CDD) which has some 100 employees and generates with its subsidiaries and branch offices in Germany, France, Spain, Netherlands, Croatia, Russia and Hungary annual sales of around EUR 10 million. NUVISAN CDD offers its clients a full range of clinical research services, especially for multinational projects of any clinical phase with a particular focus on oncology and immunology. Under new leadership of Linical, Nuvisan CDD shall grow to more then 170 employees and sales of around EUR 25 million. Linical will thus be able to cover a total of 23 countries on three continents with own employees.

TRACC LEGAL already had advised ADCURAM in the year 2010 during the acquisition of the NUVISAN Group.

Attorneys Dr. Thomas Lotz and Dr. Thorsten Steinhaus from TRACC LEGAL were responsible for the execution of the whole legal part of the complex and long-lasting transaction for their clients ADCURAM and NUVISAN Pharma Holding GmbH.